Sulphate iron

PreclinicalSmall molecule

FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Sulphate iron is one of 35 small molecule programs targeting Celiac Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Celiac DiseaseActive, not recruiting

Celiac DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Celiac Disease

#DrugCompanyPhaseTrials

Advil

KKenvue Brands

Approved

1 2

VIOKACE

DDigestive Care, Inc.

Approved

1 3

Tylenol

KKenvue Brands

Approved

1 4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—5

Sporanox

SSebela Pharmaceuticals Development LLC

Ferinject

1 7

Iron

WWatson Pharmaceuticals

Approved

1 8

Zocor

OOrganon and Co

Phase 3

1 9

Opzelura

Pfizer

Phase 2

1 10

Entyvio

Takeda

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Celiac Disease1 trial

Sucrosomial Iron in Patients With Celiac Disease and IDA

Unknown status·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·N/A·NCT02916654·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sulphate iron. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sulphate iron compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sulphate iron. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Sulphate iron

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Celiac Disease1 trial

References

Drug Info

Quick Facts

Related News